BRD4 anticorps (N-Term)
Aperçu rapide pour BRD4 anticorps (N-Term) (ABIN6952374)
Antigène
Voir toutes BRD4 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- N-Term
-
Specificité
- Polyclonal antibody raised in rabbit against human BRD4 (Bromodomain Containing 4), using two KLH-conjugated synthetic peptides from the N-terminal and central part of the protein, respectively.
-
Purification
- Peptide affinity purified
-
Immunogène
- synthetic peptide
-
-
-
-
Indications d'application
-
ChIP 2 μg:ChIP
ELISA 1:10,000
WB 1:1,000 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 2.6 μg/μL
-
Buffer
- PBS, 0.05 % azide, 0.05 % ProClin300
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C
-
-
- BRD4 (Bromodomain Containing 4 (BRD4))
-
Autre désignation
- BRD4
-
Sujet
- BRD4 (UniProt/Swiss-Prot entry O60885) is a chromatin reader protein that binds acetylated histones. It remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for gene transcription by preserving an acetylated chromatin status. As such, it plays a key role in the transmission of epigenetic memory across cell divisions. BRD4 promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II and plays a key role in regulating the transcription of signal-inducible genes. It has been implicated in a translocation of chromosome 19 which causes an upper respiratory tract carcinoma.
-
UniProt
- O60885
-
Pathways
- Chromatin Binding, SARS-CoV-2 Protein Interactome
Antigène
-